Ovarian cancer is a malignant tumour that starts in the ovary — the almond-sized organ on either side of the uterus that releases an egg every month and makes oestrogen and progesterone. It is the deadliest of the gynaecological cancers in India and worldwide, killing more women than cervical and uterine cancer combined in many countries.

There is not just one ovarian cancer; there are several biologically different types. Around 90 percent are epithelial cancers (arising from the surface lining of the ovary), and within that group the commonest subtype is high-grade serous carcinoma. Other epithelial subtypes include endometrioid, clear cell, and mucinous. About 5 to 10 percent are germ cell tumours, which arise in much younger women, sometimes in the teens and twenties. A smaller group are sex cord stromal tumours such as granulosa cell tumours, which can produce hormones and present with abnormal bleeding.

The cancer is called the silent killer because the ovaries sit deep in the pelvis with plenty of room to grow before anything noticeable happens. By the time the tumour is large enough to press on the bladder, bowel, or stomach, or has already leaked cells into the abdominal cavity, the symptoms it causes are vague — a bit of bloating, a bit of pelvic ache, feeling full quickly — exactly the symptoms most Indian women have learned to ignore as normal womanhood.

This is why awareness of the cardinal symptoms matters more than waiting for a dramatic warning sign. Early-stage ovarian cancer can be highly curable. Late-stage ovarian cancer is much harder. The gap between those two outcomes is often just a few months of paying attention.

India sees roughly 30,000 new ovarian cancer cases and around 21,000 deaths every year, according to estimates compiled from the Indian Council of Medical Research's National Cancer Registry Programme and GLOBOCAN data. Ovarian cancer is now the third most common gynaecological cancer in India after cervical and breast cancer, and the leading cause of death from gynaecological cancer.

Roughly 75 percent of Indian women with ovarian cancer are diagnosed at stage III or IV, when the cancer has already spread to the abdomen or beyond. At that stage the 5-year survival is around 30 to 50 percent. If the same cancer had been caught at stage I, the 5-year survival would have been close to 90 percent. Stage at diagnosis is the single most important predictor of outcome, and India's stage distribution is the worst part of the story.

The age peak is 50 to 70 years, but ovarian cancer is not just an older woman's disease. Germ cell tumours occur in girls and young women. BRCA-related cancers often start in the forties. Family history of breast or ovarian cancer at a young age changes the picture significantly, as we will see in the genetics section.

Awareness of ovarian cancer in Indian families remains very low compared to breast or cervical cancer. There is no national screening programme for ovarian cancer (unlike cervical), so the entire chain of early detection depends on the woman recognising a vague symptom, taking it seriously, and getting to a gynaecologist who orders the right scan and blood test. Each link of that chain is where Indian women lose time.

• Persistent bloating. Not the after-meal kind, not the once-a-month period bloating — a sense of abdominal fullness or visible distension that does not settle. Many women describe their clothes feeling tighter at the waist even though their weight has not changed. If this is happening most days for more than a couple of weeks, it deserves a gynae visit.
• Pelvic or lower abdominal pain. A dull ache, pressure, or heaviness in the pelvis or lower belly that is new for you, that does not match your usual period pattern, and that persists for weeks. It may be mild enough to ignore at first, which is part of the trap.
• Difficulty eating or feeling full quickly (early satiety). You sit down to a meal, take a few bites, and you cannot eat any more. The food sits heavily. This is one of the most under-recognised ovarian cancer symptoms in Indian women, because it is so often blamed on gastritis, indigestion, or just getting older.
• Urinary urgency or frequency. Needing to pass urine more often, more urgently, or more suddenly than before — and not because you are drinking more water. The growing ovarian mass presses on the bladder. Many women are first told they have a UTI; when the urine culture comes back negative again and again, ovarian causes deserve a look.
• The rule that matters: if any of these four symptoms is new for you, persists almost daily, and has lasted more than about 12 days in a single month, book a gynaecologist appointment. One day of bloating is not ovarian cancer. Three weeks of daily bloating, early satiety, and urinary urgency is a signal worth investigating, even if the answer turns out to be something benign.
• Two or more of the four together raise the index of suspicion further. Most women with these symptoms will not have ovarian cancer — irritable bowel, fibroids, ovarian cysts, endometriosis, and PCOS all cause similar complaints. But the cost of one investigation is far smaller than the cost of a missed diagnosis.

Beyond the four cardinal symptoms, ovarian cancer can also present with unexplained fatigue, unintentional weight loss, persistent low back pain, constipation that is new and does not respond to the usual measures, painful intercourse, and irregular vaginal bleeding (particularly in postmenopausal women).

By the time the cancer reaches the advanced stages, the symptom picture changes. Abdominal distension from ascites — fluid building up in the abdominal cavity — is one of the classic late presentations. The belly looks swollen out of proportion to the rest of the body. Severe weight loss in the limbs and face combined with a swollen abdomen is a red flag pattern.

Bowel obstruction can develop when tumour deposits coat the intestines and slow them down — vomiting, severe constipation, and abdominal pain may bring a woman to the emergency department, and ovarian cancer is sometimes first diagnosed on the CT scan ordered for that obstruction.

Shortness of breath from pleural effusion (fluid around the lung) is another late-stage presentation. The cancer can spread to the lining around the lung, particularly on the right side, and the resulting fluid can cause breathlessness on minimal exertion.

None of these late presentations is what we want. The whole point of the cardinal symptom list is to bring women to the gynaecologist long before any of this develops.

• Family history of breast or ovarian cancer is the single strongest risk factor outside age. A woman with a first-degree relative (mother, sister, daughter) with ovarian cancer has roughly three times the average risk. With two affected relatives or a personal history of early-onset breast cancer, the risk climbs further.
• BRCA1 and BRCA2 gene mutations raise the lifetime risk of ovarian cancer to roughly 40 to 60 percent (BRCA1) and 15 to 25 percent (BRCA2), compared to about 1.5 percent for the general population. That is a 10 to 20-fold increase. BRCA mutations also raise breast cancer risk and explain a meaningful fraction of ovarian cancer cases in India where multiple relatives are affected.
• Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) raises ovarian, endometrial, and colorectal cancer risk. Women with a strong family history of those three cancers together should be referred for genetic counselling.
• Personal history of breast cancer raises ovarian cancer risk, both because of shared risk factors and because of the high BRCA overlap.
• Nulliparity — never having been pregnant — raises risk modestly. Each pregnancy carried to term lowers ovarian cancer risk further. Early menarche and late menopause (more lifetime ovulations) also raise risk.
• Postmenopausal hormone replacement therapy, particularly oestrogen-only HRT used for several years, is associated with a small increase in ovarian cancer risk. The risk falls again after stopping HRT.
• Endometriosis raises the risk of certain ovarian cancer subtypes, particularly clear cell and endometrioid carcinomas. See Understanding Endometriosis: Causes, Symptoms & Management for the broader picture of that condition.
• Obesity, polycystic ovary syndrome (PCOS), and smoking (smoking specifically for the mucinous subtype) all contribute smaller amounts of risk.
• What none of these change is the central reality: around 75 percent of ovarian cancers in India are sporadic, with no family history and no obvious risk factor. Being low-risk does not exempt a woman from paying attention to the cardinal symptoms.

• Pregnancy and breastfeeding both lower ovarian cancer risk. The biological theory is that suppressing ovulation gives the ovary a rest from the repeated wound-and-repair cycle that may seed cancer over decades. Each full-term pregnancy reduces risk by about 20 percent.
• Combined oral contraceptive pill (OCP) use is one of the most powerful protective factors known. Using a combined OCP for five years or more cuts ovarian cancer risk by around 50 percent, and the protection persists for decades after stopping. For women with strong family history or BRCA mutations, OCP is often actively recommended as a risk-reducing strategy. See Birth Control Pills in India: COC, Mini-Pill, and What Actually Suits You for how OCP works and how to choose one.
• Tubal ligation (permanent sterilisation by tying the fallopian tubes) lowers ovarian cancer risk by around a third, probably because most high-grade serous cancers actually originate in the fallopian tube rather than the ovary itself.
• Hysterectomy lowers risk somewhat even when the ovaries are left in place, again partly through the fallopian tube mechanism.
• Risk-reducing salpingectomy (removing the fallopian tubes while leaving the ovaries) is increasingly offered to BRCA-positive women who have completed childbearing, or as an add-on at the time of any other pelvic surgery, as it removes the most likely site of origin without triggering surgical menopause.
• Risk-reducing salpingo-oophorectomy (removing the tubes and the ovaries together) is the most powerful preventive surgery available for BRCA-positive women, usually recommended around age 35 to 40 for BRCA1 carriers and 40 to 45 for BRCA2 carriers, once childbearing is complete. It cuts ovarian cancer risk by around 80 to 95 percent.

When a woman walks into an Indian gynae OPD with persistent bloating, pelvic pain, early satiety, or urinary urgency, the diagnostic pathway has a fairly standard shape. It starts with a pelvic examination — the gynaecologist feels for an ovarian or pelvic mass, abdominal distension, or ascites.

The first imaging is almost always transvaginal ultrasound (TVS). A small probe placed gently inside the vagina gives a clear picture of the ovaries and uterus, far better than an abdominal scan in adult women. The radiologist looks at the size of any ovarian mass, whether it is purely fluid-filled (simple cyst — usually benign) or has solid areas, papillary projections, internal walls, or thick septations (more concerning features). TVS costs roughly 500 to 2,500 rupees at private centres and is the single most important test in this workup.

Alongside the scan, the gynaecologist usually orders the CA-125 blood test. CA-125 is a tumour marker — a protein that can be elevated in ovarian cancer cells. It is most useful in postmenopausal women, where a level above 35 U/mL plus a suspicious ovarian mass on scan is highly suggestive. In premenopausal women, CA-125 is less specific because it is also raised in endometriosis, PID, fibroids, pregnancy, and even during menstruation. CA-125 costs around 500 to 2,000 rupees at private labs (Thyrocare, Metropolis, SRL, Apollo).

The Risk of Malignancy Index (RMI) is a calculation that combines the ultrasound features, the CA-125 level, and the menopausal status into a single number. A high RMI score means the woman should be referred to a gynaecologic oncologist rather than have surgery at a general centre. This referral decision is one of the most outcome-changing moments in the entire ovarian cancer pathway.

If RMI is high or the picture is otherwise suspicious, CT or MRI of the abdomen and pelvis is performed for staging — to see whether the cancer has spread to the peritoneum, lymph nodes, liver, or lungs. CT and MRI cost roughly 3,000 to 15,000 rupees at private centres, less at government hospitals.

The definitive diagnosis of ovarian cancer is made at surgery — by removing the mass, the affected ovary, and surrounding tissue and sending it for histopathology. Unlike many other cancers, fine-needle biopsy of an ovarian mass is generally avoided because it risks rupturing the capsule and spilling cancer cells into the abdomen, worsening the stage.

Ovarian cancer is staged using the FIGO (International Federation of Gynaecology and Obstetrics) system, from I to IV. Stage at diagnosis is by far the strongest predictor of how well treatment will work.

Stage I means the cancer is confined to one or both ovaries. There is no spread outside the ovary. 5-year survival is around 90 percent — most women with stage I disease are cured.

Stage II means the cancer has spread to other pelvic organs — fallopian tubes, uterus, bladder, or rectum — but has not gone beyond the pelvis. 5-year survival drops to roughly 70 percent.

Stage III means the cancer has spread beyond the pelvis into the abdomen — to the peritoneum, omentum, surface of the bowel or liver, or to regional lymph nodes. This is the stage at which most Indian women are diagnosed. 5-year survival is around 30 to 50 percent depending on how completely the surgeon can remove all visible disease.

Stage IV means distant metastasis — to the lung, inside the liver substance, or to other distant organs. 5-year survival is around 15 to 25 percent.

The number that should drive Indian conversations about ovarian cancer is not the survival number for advanced disease. It is the gap between stage I and stage III — 90 percent versus 30 to 50 percent. That gap is where awareness of the cardinal symptoms genuinely changes outcomes.

• Stage I (and selected Stage II) is treated with surgery — total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO), omentectomy, and lymph node sampling. For young women with very early Stage IA who want future fertility, a more conservative operation preserving the uterus and one ovary is sometimes possible at specialist centres. Adjuvant chemotherapy is offered for higher-grade Stage I and most Stage II cases.
• Stage III and Stage IV are treated with a combination of primary cytoreductive (debulking) surgery plus chemotherapy. The aim of debulking surgery is to remove as much visible cancer as possible — the closer to zero residual disease, the better the survival. This is highly skilled surgery and is best done at a comprehensive cancer centre by a gynaecologic oncologist.
• Standard first-line chemotherapy is the combination of carboplatin and paclitaxel given intravenously every three weeks for six cycles. The combination is well-established globally and routinely available across Indian cancer centres. Side effects include hair loss, fatigue, low blood counts, and peripheral neuropathy.
• PARP inhibitors — oral targeted therapy drugs such as olaparib and niraparib — are now part of maintenance therapy after first-line chemotherapy for women with BRCA-mutated ovarian cancer and increasingly for other subgroups too. They significantly extend the disease-free interval. The cost is high (often several lakhs per year), though PMJAY and patient assistance programmes from the manufacturers may help eligible patients.
• Neoadjuvant chemotherapy — giving chemotherapy first and surgery second — is an alternative for women with very advanced disease who are not fit for upfront extensive surgery. Three cycles of chemotherapy shrink the tumour, surgery removes what is left, and three more cycles of chemotherapy follow.
• Hyperthermic intraperitoneal chemotherapy (HIPEC) involves bathing the abdomen with heated chemotherapy at the end of debulking surgery. It is available at selected Indian centres and is offered to carefully chosen patients with peritoneal disease.
• Recurrent ovarian cancer is common in advanced disease. Second-line and later treatments include further chemotherapy regimens, PARP inhibitors, and emerging immunotherapy and antibody-drug conjugate options at major centres.

Genetic testing for BRCA1 and BRCA2 mutations is one of the most powerful tools available to Indian families with a strong personal or family history of breast or ovarian cancer. A positive result does not mean cancer will happen — it means the lifetime risk is significantly higher than average and that several powerful preventive options become available.

Testing should be considered for women with personal or family history of breast or ovarian cancer at a young age (under 50 for breast, any age for ovarian), multiple first-degree relatives affected, male breast cancer in the family, triple-negative breast cancer under 60, or a known BRCA-positive relative. Ashkenazi Jewish ancestry carries higher BRCA prevalence but is uncommon in India.

The test itself is a blood draw or saliva sample. In India, BRCA1 and BRCA2 panel testing typically costs 15,000 to 50,000 rupees at private genetic testing labs (MedGenome, Mapmygenome, Strand, Centogene, Lal PathLabs partners). Larger hereditary cancer panels that also cover Lynch syndrome and other genes are available at the higher end of that range. PMJAY covers genetic testing at some empanelled cancer centres for eligible patients.

Pre-test and post-test genetic counselling is the most important part of the process. A counsellor or specialist explains what positive, negative, and variant-of-uncertain-significance results mean, what they imply for the woman herself, and what they imply for her sisters, daughters, and other relatives. Testing without counselling can do real harm; testing with counselling can change family futures.

For a BRCA-positive woman, the preventive options include high-intensity surveillance (annual CA-125 plus TVS plus breast MRI), combined OCP for ovarian cancer risk reduction, and risk-reducing salpingo-oophorectomy after childbearing — typically at age 35 to 40 for BRCA1 and 40 to 45 for BRCA2. Risk-reducing mastectomy is a separate decision on the breast side. None of these is mandatory; all are choices the woman makes with her care team.

• Ayushman Bharat PMJAY covers ovarian cancer surgery, chemotherapy, and most diagnostic workup for eligible families up to 5 lakh rupees a year. Cashless treatment is available at empanelled hospitals across India. For a complex case the annual limit may not cover everything, but it covers the majority of standard care.
• Comprehensive cancer centres are where ovarian cancer should ideally be treated, because survival in stage III and IV depends heavily on the experience of the surgical team. The national leaders include Tata Memorial Hospital (Mumbai), the broader AIIMS network (Delhi, Bhubaneswar, Bhopal, Jodhpur, Patna, Raipur, Rishikesh and the new AIIMS), Christian Medical College (CMC) Vellore, JIPMER Puducherry, Kidwai Memorial Institute of Oncology (Bengaluru), Cancer Institute (WIA) Chennai, and Tata Memorial Centre Varanasi, alongside private cancer chains like HCG, Apollo, and Fortis with dedicated gynaecologic oncology units.
• Surgery cost in the private sector typically runs 50,000 to 3,00,000 rupees depending on the centre, the surgeon, and the complexity. Public sector and PMJAY pricing is dramatically lower.
• Chemotherapy with carboplatin and paclitaxel costs roughly 15,000 to 50,000 rupees per cycle privately for the drugs and admission; six cycles is the usual course. Government cancer hospitals provide it at very low or no cost.
• PARP inhibitors are the most expensive piece of the treatment puzzle — olaparib and niraparib can cost several lakhs per year. Patient assistance programmes from manufacturers and PMJAY at some empanelled centres can substantially reduce out-of-pocket cost.
• BRCA genetic testing costs 15,000 to 50,000 rupees at private labs, with PMJAY coverage available at some empanelled centres. Even when paid out-of-pocket, this is usually a one-time test that informs decades of surveillance and prevention decisions for the whole family.

• Myth: a Pap smear will pick up ovarian cancer. Fact: Pap smears screen the cervix only, not the ovaries. A normal Pap is reassuring for cervical cancer but tells you nothing about the ovaries. For broader cervical screening context see cervical-cancer-india-screening.
• Myth: only older women get ovarian cancer. Fact: the age peak is 50 to 70, but germ cell tumours can occur in teens and twenties, and BRCA-related cancers often present in the forties.
• Myth: if there is no family history, there is no risk. Fact: around 75 percent of ovarian cancers are sporadic, with no family history at all. Being low-risk does not mean being no-risk, and the cardinal symptoms still matter.
• Myth: an ovarian cyst always becomes cancer. Fact: most ovarian cysts in premenopausal women are benign functional cysts that come and go with the monthly cycle. The features that matter are size, solid components, the woman's age, and CA-125. For a fuller guide to when an ovarian cyst is worrying see ovarian-cysts-types-and-when-to-worry-india.
• Myth: persistent bloating is just irritable bowel. Fact: sometimes it is, and IBS is much more common than ovarian cancer. But persistent daily bloating for more than about 12 days in a month, especially with one of the other cardinal symptoms, deserves at minimum a TVS and a CA-125 before being labelled IBS.
• Myth: a CA-125 test is a screening test for ovarian cancer. Fact: CA-125 is not a screening test for the general population. It is used when there is a symptom or pelvic mass under investigation. Routine CA-125 testing of asymptomatic average-risk women causes more harm (false alarms, unnecessary surgery) than good.
• Myth: if I removed my uterus I cannot get ovarian cancer. Fact: a hysterectomy that left the ovaries in place still leaves ovarian cancer possible. Risk is somewhat lower, but the cardinal symptoms still apply.